Explore how E-selectin-targeted polymer-doxorubicin therapy induces regression in colorectal liver metastases.

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

Previously, NMPA has accepted two supplemental new drug applications (sNDA) seeking the approvals of sac-TMT monotherapy for the treatment of patients with locally advanced or metastatic EGFR-mutant ...

Cancer metabolism is a critical area of research, central to understanding how malignant tumors manipulate metabolic pathways to support their growth and survival. These alterations not only fuel ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...

CNSide can aid the diagnosis and management of leptomeningeal metastases in patients with cancer, a new study suggests.

A team of researchers led by Professor Ningling Kang, PhD, at The Hormel Institute, University of Minnesota, has published an ...

Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.

TuHURA Biosciences (HURA) provided a business update and outlined upcoming targeted milestones. “We have made significant progress toward ...